PERIOPERATIVE TREATMENT WITH COI-B (CAPECITABINE, OXALIPLATIN, IRINOTECAN AND BEVACIZUMAB) OF HIGH RISK OR BORDERLINE RESECTABLE COLORECTAL CANCER LIVER METASTASES (COI-B)
Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
This PHASE2 trial investigates Colorectal Cancer Liver Metastases and is currently completed. Fondazione IRCCS Istituto Nazionale dei Tumori, Milano leads this study, which shows 7 recorded versions since 2013 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Sep 2019 — Jan 2021 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jun 2018 — Sep 2019 [monthly]
Active Not Recruiting PHASE2
▶ Show 2 earlier versions
-
Sep 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jan 2017 — Sep 2017 [monthly]
Recruiting PHASE2
First recorded
Jun 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
For direct contact, visit the study record on ClinicalTrials.gov .